Infinium Pharmachem Ltd
₹222.95
-1.09%
Delayed · cached 15 min
Fair value analysis
INFINIUM
Infinium Pharmachem Ltd
₹274.00
Close used for this calculation
₹231.42Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
35/100
Quality radar
Consensus fair value
₹231.42
Above FV▼ -15.5% against the close used
Model range ₹70.20 – ₹314.52
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹70.20Fair value₹231.42Bull₹314.52
FairClose
52-week traded range
52W low ₹191.0552W high ₹283.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Infinium Pharmachem Ltd closed at ₹274.00, 18.4% above the consensus fair value of ₹231.42 drawn from 9 valuation models.
Financial DNA score 35/100 — Average. P/E of 34.1x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹314.52
+14.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹118.58
-56.7%
√(22.5 × EPS × BVPS)
EPS=7.8, BVPS=80.12 · outside Graham range (P/E 34.1, P/B 3.4) — asset-light, treat as a rough floor
Graham Formula
₹191.94
-30.0%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=9%, FD=7%
P/E Fair Value
₹278.46
+1.6%
EPS × 35.7x (sector P/E)
EPS=7.8, Sector P/E=35.7x
Peter Lynch (PEG)
₹70.20
-74.4%
EPS × Growth% (PEG = 1 is fair)
EPS=7.8, g=9%
EV/EBITDA
₹239.34
-12.7%
(EBITDA × 14.5x − Net Debt) ÷ Shares
EBITDA=250M
Book Value (P/B)
₹90.13
-67.1%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=80.12, ROE=10.5%, g=6%, r=10%
Reverse DCF
₹274.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 14.7% | Historical: 9%
Margin of Safety
₹169.41
-38.2%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=225.88, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.